INTerpath-001's Full Phase 3 Data Are In: What Moderna and Merck's Personalized Melanoma Vaccine Actually Showed

What this article covers
- What This Article Covers
- Back in August 2026, the developers announced that their personalized mRNA cancer vaccine, intismeran autogene (formerly mRNA-4157/V940), had met its primary endpoints in INTerpath-001 — the first Phase 3 trial of an individualized, tumor-sequencing-based cancer vaccine ever to succeed — but withheld the actual numbers until a scheduled Presidential Symposium at the ESMO Congress in Madrid. On October 23–24, 2026, that full dataset finally arrived.
- What Happened
- Intismeran autogene is built individually for each patient: after a tumor is surgically removed, its mutations are sequenced, and an algorithm selects up to 34 patient-specific neoantigens, which are then encoded into a single synthetic mRNA shot. The idea is to train the immune system to recognize and attack any melanoma cells that share that patient's unique mutational signature — a custom-built vaccine against one person's cancer, given alongside a checkpoint inhibitor that keeps T cells active.
- What the Phase 3 Data Actually Show
- INTerpath-001 (NCT05933577) randomized 1,137 patients with completely resected, high-risk Stage IIB through IV cutaneous melanoma in a 2:1 ratio to intismeran plus pembrolizumab (757 patients) or placebo plus pembrolizumab (380 patients).
- The Catch: Why Wall Street Wasn't Impressed
- Here's where accuracy requires pulling back the optimism a notch. The Phase 3 risk reduction (42% for RFS) is meaningfully smaller than the Phase 2b figure (49%) that first made headlines, and the Phase 3 DMFS benefit (38%) likewise trailed the Phase 2b read (59%).
- What This Means for Patients
- For people with resected, high-risk melanoma, this is the first large, randomized trial to show that adding a personalized neoantigen vaccine to standard pembrolizumab therapy meaningfully lowers the chance the cancer comes back or spreads — a real, additive benefit on top of today's standard of care. Dr.
What This Article Covers
Back in August 2026, the developers announced that their personalized mRNA cancer vaccine, intismeran autogene (formerly mRNA-4157/V940), had met its primary endpoints in INTerpath-001 — the first Phase 3 trial of an individualized, tumor-sequencing-based cancer vaccine ever to succeed — but withheld the actual numbers until a scheduled Presidential Symposium at the ESMO Congress in Madrid. On October 23–24, 2026, that full dataset finally arrived. The vaccine, paired with the checkpoint inhibitor pembrolizumab (Keytruda), significantly reduced the risk of melanoma recurrence and distant metastasis after surgery compared with pembrolizumab alone. It's a genuine milestone — the first time this entire class of individualized cancer vaccines has cleared a randomized, controlled Phase 3 bar with full data in hand. It also arrived with a smaller effect size than the earlier, smaller trial had suggested, immature overall-survival numbers, and a market reaction that punished both companies' stock. This article walks through what the full trial data actually found, what it means for melanoma patients today, and why the "home run" framing from 2023 has given way to something more modest, but still real.
What Happened
Intismeran autogene is built individually for each patient: after a tumor is surgically removed, its mutations are sequenced, and an algorithm selects up to 34 patient-specific neoantigens, which are then encoded into a single synthetic mRNA shot. The idea is to train the immune system to recognize and attack any melanoma cells that share that patient's unique mutational signature — a custom-built vaccine against one person's cancer, given alongside a checkpoint inhibitor that keeps T cells active.
The approach first showed promise in the Phase 2b KEYNOTE-942 trial, which reported in late 2022 that the combination cut the risk of recurrence or death by 49% compared with pembrolizumab alone, with the benefit holding up through five years of follow-up reported earlier in 2026. That data, plus FDA Breakthrough Therapy Designation (granted in February 2023) and an EMA PRIME designation, generated substantial excitement — and high expectations for the confirmatory Phase 3 trial.
What the Phase 3 Data Actually Show
INTerpath-001 (NCT05933577) randomized 1,137 patients with completely resected, high-risk Stage IIB through IV cutaneous melanoma in a 2:1 ratio to intismeran plus pembrolizumab (757 patients) or placebo plus pembrolizumab (380 patients). At a median follow-up of 24.6 months, the trial met its primary endpoint:
- Recurrence-free survival (RFS): hazard ratio 0.58 (95% CI, 0.45–0.75; p<.001) — a 42% reduction in the risk of recurrence or death. Two-year RFS was 82.2% with the combination versus 70.0% with pembrolizumab alone.
- Distant metastasis-free survival (DMFS), the key secondary endpoint: hazard ratio 0.62 (95% CI, 0.45–0.85; p=.002) — a 38% reduction in risk. Two-year DMFS was 88.5% versus 80.2%.
- Overall survival: hazard ratio 0.77 (95% CI, 0.45–1.31; p=.33) — a favorable trend, but not statistically significant, with follow-up still ongoing.
Notably, the benefit wasn't immediate. In the first six months after treatment began, the RFS hazard ratio sat right around 1.0 (0.99), meaning no detectable difference between arms yet. Beyond six months, it dropped to 0.42 — a substantial, durable effect that simply took time to emerge. The manufacturing side held up well in practice, too: the personalized vaccine was successfully produced for more than 99% of patients assigned to receive it, with a median time from randomization to first dose of 64 days.
Safety was consistent with what's already known about each component. Treatment-related adverse events were more common with the combination (95.8% vs. 90.0%), driven mostly by injection-related effects — pyrexia (52.2% vs. 8.2%), injection site pain (51.0% vs. 9.5%), and flu-like illness (25.4% vs. 9.2%), described as low-grade and transient. Serious grade 3 or higher treatment-related toxicity was similar between arms (14.2% vs. 13.4%), and immune-related adverse events — the ones tied specifically to pembrolizumab — occurred at nearly identical rates (36.0% vs. 34.7%), indicating the vaccine did not amplify the checkpoint inhibitor's known risks. Two treatment-related deaths occurred in the combination arm; both were attributed to pembrolizumab, none to intismeran.
The Catch: Why Wall Street Wasn't Impressed
Here's where accuracy requires pulling back the optimism a notch. The Phase 3 risk reduction (42% for RFS) is meaningfully smaller than the Phase 2b figure (49%) that first made headlines, and the Phase 3 DMFS benefit (38%) likewise trailed the Phase 2b read (59%). The lead developer's shares dropped roughly 21% on the day detailed data leaked ahead of the scheduled embargo, and a Wall Street Journal headline captured the sentiment bluntly: "Moderna's Cancer Success Doesn't Live Up to Early Hype." Investors had priced in the larger, smaller-trial numbers; the larger, more rigorous trial brought them back toward earth. That's a market story, not necessarily a clinical one — a statistically significant, double-digit percentage reduction in recurrence risk in a 1,137-patient randomized trial is still a real and clinically meaningful result, even if it's a more modest home run than the first swing suggested.
What This Means for Patients
For people with resected, high-risk melanoma, this is the first large, randomized trial to show that adding a personalized neoantigen vaccine to standard pembrolizumab therapy meaningfully lowers the chance the cancer comes back or spreads — a real, additive benefit on top of today's standard of care. Dr. Patrick Ott, who served on the trial's scientific advisory board, called it "remarkable" to see this effect "with an entirely new therapy that has a very different way of action," while lead investigator Dr. Georgina Long described the results as potentially "transformative" for adjuvant melanoma care. Beyond melanoma, the same platform is already being tested in Phase 3 trials for non-small cell lung cancer and in earlier-stage trials for pancreatic and gastric cancers, so a confirmed win here matters well beyond one tumor type.
Caveats and Open Questions
Overall survival data remain immature, and it's not yet proven that preventing recurrence translates into more years of life — that readout is still pending. Manufacturing each dose individually takes roughly six to eight weeks per patient, and analysts have floated prices near $400,000 per course, raising real questions about cost, access, and logistics even if regulators eventually approve it. The trial excluded 17.3% of initially screened patients because their tumor samples weren't adequate for sequencing, a real-world limitation on who can actually receive this therapy. Intismeran plus pembrolizumab remains fully investigational, with no confirmed regulatory filing date yet announced.
Bottom Line
INTerpath-001's full data confirm a legitimate first for cancer immunotherapy: a personalized, tumor-sequencing-based mRNA vaccine has cleared a randomized Phase 3 trial, cutting the risk of melanoma recurrence by 42% and distant metastasis by 38% when added to standard checkpoint inhibitor therapy, with a manageable, mostly injection-related side-effect profile. It is not the slam-dunk the earlier, smaller trial hinted at, and overall survival benefit is not yet established — but for a disease where recurrence after surgery remains common, a statistically significant, safety-consistent improvement in a trial of this size is genuine progress, not hype. Regulatory review and a full peer-reviewed publication (reportedly accepted by the New England Journal of Medicine) are the next milestones to watch.
This is a follow-up to our earlier article, "First-Ever Personalized Cancer Vaccine Clears a Phase 3 Trial — A Milestone for Melanoma Patients" (October 9, 2026), which covered the August 2026 topline announcement.
Key Questions Answered
- What did INTerpath-001 find?
- Adding intismeran to pembrolizumab cut the risk of melanoma recurrence or death by 42% (HR 0.58) and distant metastasis by 38% (HR 0.62) versus pembrolizumab alone in 1,137 patients.
- Did the vaccine improve overall survival?
- Not yet proven. The overall survival hazard ratio of 0.77 was a favorable trend but not statistically significant, and follow-up continues.
- Is the vaccine approved?
- No. Intismeran plus pembrolizumab remains investigational, with no confirmed regulatory filing date announced.
Sources
- INTerpath-001 Data Detail Survival, Subgroup, and Safety Findings in Melanoma, CancerNetwork, October 24, 2026 — https://www.cancernetwork.com/view/interpath-001-data-detail-survival-subgroup-and-safety-findings-in-melanoma
- Personalized mRNA Vaccine Reduced Melanoma Recurrence Risk 42% After Surgery, Healio/HemOnc Today, October 23, 2026 — https://www.healio.com/news/hematology-oncology/20261023/personalized-mrna-vaccine-reduced-melanoma-recurrence-risk-42-after-surgery
- Intismeran Plus Pembrolizumab Reduces Recurrence Risk in Resected Melanoma, CancerNetwork, October 22, 2026 — https://www.cancernetwork.com/view/intismeran-plus-pembrolizumab-reduces-recurrence-risk-in-resected-melanoma
- 5 Things You Should Know About Intismeran, the Moderna-Merck Cancer Vaccine, Managed Healthcare Executive, October 26, 2026 — https://www.managedhealthcareexecutive.com/view/5-things-you-should-know-about-intismeran-the-moderna-merck-cancer-vaccine
- Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA (pembrolizumab) at ESMO 2026 Presidential Symposium, Merck.com, 2026 — https://www.merck.com/news/merck-and-moderna-will-present-results-from-landmark-phase-3-interpath-001-trial-for-intismeran-autogene-plus-keytruda-pembrolizumab-at-esmo-2026-presidential-symposium
Related Articles
- Research & Industry
ASCO Annual Meeting 2027: What to Expect From Oncology's Biggest Stage
The world's largest clinical oncology meeting returns to Chicago in June 2027, with cell therapy, immunotherapy, and antibody-drug conjugate research expected to headline the scientific program once again.
- Research & Industry
AACR IO 2027: What to Expect From the Immuno-Oncology Conference Coming to Los Angeles
AACR IO 2027 meets in Los Angeles February 28–March 3, focusing on cancer vaccines, engineered T cells and early clinical data—not confirmed treatment advances.
- Research & Industry
CAR-T Therapy for Autoimmune Disease in France: What's Actually Happening
France hosts investigational CAR-T trials for severe lupus, but September 2026 safety pauses underscore serious risks and the absence of an approved autoimmune therapy.